LON:AVO - Advanced Oncotherapy Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 52.50 +1.00 (+1.94 %)
(As of 07/16/2018 04:00 PM ET)
Previous CloseGBX 51.50
Today's RangeGBX 52 - GBX 54.70
52-Week RangeGBX 9.75 - GBX 64.80
Volume122,616 shs
Average Volume79,755 shs
Market Capitalization£41.31 million
P/E RatioN/A
Dividend YieldN/A
Advanced Oncotherapy logoAdvanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. It is involved in developing Linac Image Guided Hadron technology, a proton therapy system for treating cancer. The company is also involved in the management of a healthcare related property. It operates in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive AVO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Medical Devices


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-43.18%
Return on Assets-35.03%


Outstanding Shares80,940,000
Market Cap£41.31

The Truth About Cryptocurrencies

Advanced Oncotherapy (LON:AVO) Frequently Asked Questions

What is Advanced Oncotherapy's stock symbol?

Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

What is the consensus analysts' recommendation for Advanced Oncotherapy?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Advanced Oncotherapy's key competitors?

Who are Advanced Oncotherapy's key executives?

Advanced Oncotherapy's management team includes the folowing people:
  • Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 75)
  • Mr. Nicolas Serandour, CEO & Exec. Director
  • Dr. Sanjeev Pandya, Exec. VP for Global Bus. Devel. and Exec. Director
  • Mr. Ed Lee, COO & Sr. VP of Operations
  • Mr. Graham Pughe, Sr. VP of Accounting & IT

Has Advanced Oncotherapy been receiving favorable news coverage?

Media stories about AVO stock have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Advanced Oncotherapy earned a coverage optimism score of 0.14 on Accern's scale. They also assigned media stories about the company an impact score of 45.17 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Advanced Oncotherapy?

Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Advanced Oncotherapy's stock price today?

One share of AVO stock can currently be purchased for approximately GBX 52.50.

How big of a company is Advanced Oncotherapy?

Advanced Oncotherapy has a market capitalization of £41.31 million.

How can I contact Advanced Oncotherapy?

Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728.

MarketBeat Community Rating for Advanced Oncotherapy (LON AVO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote "Outperform" if you believe AVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.